Recce Pharmaceuticals’ Expert KOL Webinar: How R327 is leading the way as a potential, robust solution to Sepsis and Superbugs

06/21/2022 - 06/21/2022
8:00 am - 9:00 am EDT
The event will feature a presentation from Key Opinion Leader Thomas Heymann (President & CEO of Sepsis Alliance, USA), who will discuss the current treatment landscape and unmet medical need in treating patients with sepsis.
Sepsis patient advocate Mary Millard (International Speaker, Hospital Infections & Prevention) will speak about her journey, the unmet need, and the current standard of care in place. The Recce leadership team will discuss RECCE® 327 intravenous formulation as a potential novel treatment solution.
A live question and answer session will follow.